Details
Protocol and report for a project to assess the impact of the 2010 FDA regulatory action on long acting beta2 agonists (LABAs) on drug utilization patterns. The protocol represents a customized study design.
Additional Information
Contributors
Melissa Butler PharmD, MPH, PhD; Kaiser Permanente of Georgia, Center for Health Research Southeast, Atlanta, GA
Esther Zhou MD, PhD; Center for Drug and Evaluation Research, FDA, Silver Spring, MD
Meghan A. Baker MD, ScD; Brigham and Women's Hospital, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Monika Houstoun PharmD; Solomon Iyasu MD, MPH; Mark Levenson PhD; Marsha Reichman PhD; Sally Seymour MD; Yu-te Wu PhD; Center for Drug and Evaluation Research, FDA, Silver Spring, MD
Darren Toh ScD; Fang Zhang PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Ann Wu MD, MPH; Boston Children's Hospital, Boston, MA; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Pingsheng Wu PhD; Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN